Premium
Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A 1 ‐receptor agonist N 6 ‐(p‐sulphophenyl)adenosine in rats
Author(s) -
Schaick E. A.,
Greef H. J. M. M.,
Langemeijer M. W. E.,
Sheehan M. J.,
IJzerman A. P.,
Danhof M.
Publication year - 1997
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0701412
Subject(s) - adenosine , agonist , adenosine receptor , chemistry , pharmacodynamics , pharmacology , adenosine a1 receptor , pharmacokinetics , receptor , endocrinology , medicine , biochemistry
1 The purpose of this study was to develop and validate an integrated pharmacokinetic‐pharmacodynamic model for the anti‐lipolytic effects of the adenosine A 1 ‐receptor agonist N 6 ‐(p‐sulphophenyl)adenosine (SPA). Tissue selectivity of SPA was investigated by quantification of haemodynamic and anti‐lipolytic effects in individual animals. 2 After intravenous infusion of SPA to conscious normotensive Wistar rats, arterial blood samples were drawn for determination of blood SPA concentrations, plasma non‐esterified fatty acid (NEFA) and β‐hydroxybutyrate levels. Blood pressure and heart rate were monitored continuously. 3 The relationship between the SPA concentrations and the NEFA lowering effect was described by the indirect suppression model. Administration of SPA at different rates and doses (60 μg kg −1 in 5 min and 15 min, and 120 μg kg −1 in 60 min) led to uniform pharmacodynamic parameter estimates. The averaged parameters (mean±s.e., n =19) were E max : −80±2% (% change from baseline), EC 50 : 22±2 ng ml −1 , and Hill factor: 2.2±0.2. 4 In another group, given 400 μg kg −1 SPA in 15 min, pharmacodynamic parameters for both heart rate and anti‐lipolytic effect were derived within the same animal. The reduction in heart rate was directly related to blood concentration on the basis of the sigmoidal E max model. SPA inhibited lipolysis at concentrations lower than those required for an effect on heart rate. The EC 50 values (mean±s.e., n =6) were 131±31 ng ml −1 and 20±3 ng ml −1 for heart rate and NEFA lowering effect, respectively. 5 In conclusion, the relationship between blood SPA concentrations and anti‐lipolytic effect was adequately described by the indirect suppression model. For SPA a 6 fold difference in potency was observed between the effects on heart rate and NEFAs, indicating some degree of tissue selectivity in vivo .British Journal of Pharmacology (1997) 122 , 525–533; doi: 10.1038/sj.bjp.0701412